“Anybody who thinks AI can’t replace part of their job is mistaken.” – Dr. Jonathan Kaplan

In this episode of Compound Wisdom, Steve Sood sits down with Dr. Jonathan Kaplan, board-certified plastic surgeon and founder of Dr. Well, to break down the collision between telehealth, GLP-1s, peptides, AI, and the future of provider-owned healthcare platforms.

Jonathan walks through his path from scrubbing into surgeries at age 11 in Louisiana to launching a price-transparency tool for cosmetic procedures, which eventually evolved into a national provider-to-consumer telehealth infrastructure serving 200+ practices. What started as solving a simple pricing problem turned into subscriptions, weight management programs, and ultimately a scalable compounding-backed medication platform.

The conversation moves beyond surface-level GLP hype and into structural realities: continuity of care vs independent contractor telehealth models, 503A pharmacy strategy, regulatory risk around research-use peptides, and why most operators misunderstand compounding economics. Jonathan explains the development of GLP-1 Squared (a semaglutide + tirzepatide combination), why differentiation matters in a tightening regulatory environment, and how serious players are preparing for FDA scrutiny rather than avoiding it.

They also go deep on AI — not just as a buzzword, but as infrastructure. From asynchronous smart consults to autonomous surgical robotics, Jonathan argues that AI will penetrate every layer of medicine faster than most expect. The real question isn’t whether it happens — it’s who adapts responsibly.

The episode closes with insights on longevity demand, peptide reclassification, Big Pharma acquisition behavior, and how social media — when done strategically — can drive real patient acquisition instead of vanity metrics.

This is a grounded conversation about operator leverage, regulatory positioning, and building healthcare models that can survive the next 24 months.

Takeaways

Dr. Kaplan began observing surgeries at age 11 and chose plastic surgery at 16.
Early frustration with cosmetic price opacity led him to build a pricing automation tool.
That tool evolved into BuildMyHealth and later Dr. Well.
Dr. Well operates as a provider-to-consumer (PTC) platform, not DTC.
Continuity of care is the structural weakness in many telehealth models.
GLP-1 subscriptions created infrastructure for scaling compounded meds.
GLP-1 Squared combines semaglutide + tirzepatide in a differentiated formulation.
Patent filings and IND pathways signal long-term positioning, not short-term arbitrage.
Research-use-only peptides carry legal and liability exposure.
503A pharmacies will likely replace gray-market labs over time.
AI is being used internally for platform acceleration, not autonomous prescribing (yet).
Autonomous robotic surgery is likely closer than most assume.
Longevity demand is expanding the total addressable market, not shrinking it.
Big Pharma will likely acquire longevity-focused startups rather than build internally.
Social media growth requires algorithm fluency and constant adaptation.
MiniChat-style automation improves patient conversion workflows.
Head-banging persistence preceded viral growth.
GLP-1 adoption acts as a gateway into broader longevity experimentation.
Compliance-first models will outlast Shopify-style gray sellers.
Infrastructure ownership > trend chasing.

Chapters

00:00 – Early exposure to surgery and choosing plastic surgery

02:30 – Cosmetic pricing frustration and tech origins

04:20 – From price estimator to telehealth infrastructure

06:00 – Provider-to-consumer vs direct-to-consumer models

08:40 – GLP-1 growth and subscription mechanics

10:30 – Building GLP-1 Squared and regulatory differentiation

13:00 – Compounding, 503A strategy, and risk tolerance

15:20 – AI in platform development

17:00 – Autonomous surgery and timeline predictions

19:30 – Peptides, Category 2 status, and reclassification outlook

22:00 – Longevity demand and market expansion

24:10 – Big Pharma acquisition behavior

26:00 – Personal stack: GLP-1 Squared + NAD

28:30 – Social media growth strategy and viral moments

31:00 – Automation, MiniChat, and conversion systems

33:30 – Blind question and closing thoughts

Takeaways

Chapters

Tags